NCT04830202Temporarily Not Available不适用
Expanded Access to Telisotuzumab Vedotin
AbbVie0 个研究点开始时间: 2021年4月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Temporarily Not Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 接受健康志愿者
- 否
入选标准
- •Exclusion Criteria:
- •There are other suitable treatment options.
- •The participant qualifies for ongoing clinical trials.
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
No Longer Available
不适用
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
Available
不适用
A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspUveal MelanomaNCT04960891Immunocore Ltd